These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22659735)

  • 1. Sarcomas as a mise en abyme of mesenchymal stem cells: exploiting interrelationships for cell mediated anticancer therapy.
    Burns JS; Safwat A; Grisendi G; Kassem M; Dominici M
    Cancer Lett; 2012 Dec; 325(1):1-10. PubMed ID: 22659735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.
    Grisendi G; Spano C; D'souza N; Rasini V; Veronesi E; Prapa M; Petrachi T; Piccinno S; Rossignoli F; Burns JS; Fiorcari S; Granchi D; Baldini N; Horwitz EM; Guarneri V; Conte P; Paolucci P; Dominici M
    Stem Cells; 2015 Mar; 33(3):859-69. PubMed ID: 25420617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
    Xu S; De Becker A; De Raeve H; Van Camp B; Vanderkerken K; Van Riet I
    Biochem Biophys Res Commun; 2012 Aug; 424(3):391-7. PubMed ID: 22771324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas.
    Honoki K; Tsujiuchi T
    Expert Rev Anticancer Ther; 2013 Aug; 13(8):983-96. PubMed ID: 23984899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cardiac sarcomas may develop from resident or bone marrow-derived mesenchymal stem cells: use of immunohistochemistry including CD44 and octamer binding protein 3/4.
    Hegyi L; Thway K; Fisher C; Sheppard MN
    Histopathology; 2012 Nov; 61(5):966-73. PubMed ID: 22804494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
    Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence cancer stem cells--made by cell fusion?
    Dittmar T; Nagler C; Schwitalla S; Reith G; Niggemann B; Zänker KS
    Med Hypotheses; 2009 Oct; 73(4):542-7. PubMed ID: 19564079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cells: From stem cells to sarcomas.
    Lye KL; Nordin N; Vidyadaran S; Thilakavathy K
    Cell Biol Int; 2016 Jun; 40(6):610-8. PubMed ID: 26992453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
    Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cells in sarcomas: Getting to the stemness core.
    Skoda J; Veselska R
    Biochim Biophys Acta Gen Subj; 2018 Oct; 1862(10):2134-2139. PubMed ID: 30003939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
    Grisendi G; Bussolari R; Cafarelli L; Petak I; Rasini V; Veronesi E; De Santis G; Spano C; Tagliazzucchi M; Barti-Juhasz H; Scarabelli L; Bambi F; Frassoldati A; Rossi G; Casali C; Morandi U; Horwitz EM; Paolucci P; Conte P; Dominici M
    Cancer Res; 2010 May; 70(9):3718-29. PubMed ID: 20388793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells.
    Despeaux M; Labat E; Gadelorge M; Prade N; Bertrand J; Demur C; Recher C; Bonnevialle P; Payrastre B; Bourin P; Racaud-Sultan C
    Leukemia; 2011 Nov; 25(11):1789-93. PubMed ID: 21647157
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
    Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
    Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice.
    Galiè M; Konstantinidou G; Peroni D; Scambi I; Marchini C; Lisi V; Krampera M; Magnani P; Merigo F; Montani M; Boschi F; Marzola P; Orrù R; Farace P; Sbarbati A; Amici A
    Oncogene; 2008 Apr; 27(18):2542-51. PubMed ID: 17998939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-γ-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand.
    Du J; Zhou L; Chen X; Yan S; Ke M; Lu X; Wang Z; Yu W; Xiang AP
    Int J Biochem Cell Biol; 2012 Aug; 44(8):1305-14. PubMed ID: 22554587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF; Erff M; Ashkenazi A
    Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.
    Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS
    Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma.
    De Vito C; Riggi N; Cornaz S; Suvà ML; Baumer K; Provero P; Stamenkovic I
    Cancer Cell; 2012 Jun; 21(6):807-21. PubMed ID: 22698405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo.
    Mueller LP; Luetzkendorf J; Widder M; Nerger K; Caysa H; Mueller T
    Cancer Gene Ther; 2011 Apr; 18(4):229-39. PubMed ID: 21037557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.